Resistance drivers to CDK4/6i have been identified through clinical and preclinical studies, and efforts are ongoing to delineate genomic patterns of response and resistance over the course of CDK4/6i ...

APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy The following represents ...

Taletrectinib in ROS1 Fusion–Positive Non–Small Cell Lung Cancer: Promising Yet Premature? The following represents disclosure information provided by authors of this manuscript. All relationships are ...

Another compounding problem in the region is the lack of clinical studies for ICI. The genomic drivers of patients with cancer in SEA still remain poorly understood, hindering the development of ...

Baseline Brain Metastasis Imbalance in TRUST: Implications for Interpreting Intracranial Efficacy of Taletrectinib ...

In the article that accompanies this editorial, 4 the KEYNOTE-585 trial demonstrated that adding pembrolizumab to perioperative chemotherapy with fluorouracil and cisplatin in resectable ...